Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 224-228

  Klaassen, U ^a   Harstrick, A ^a   Schleucher, N ^a   Vanhoefer, U ^a   Schroder J ^a   Wilke, H ^a   Seeber, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Drug interaction; Etoposide; Hydroperoxy ifosfamide; Ovarian cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; STOMACH CARCINOMA;

EID: 0030054417     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.341     Document Type: Article

References (12)

1. BERENBAUM MC. (1989). What is synergy? Pharmacol. Rev., 41, 93-140.
2. HAMILTON TC, WINKER MA AND LOUIE KC (1985). Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol., 34, 2583-2586.
3. JEKUNEN AP, CHRISTEN RD, SHALINSKY DR AND HOWELL SB. (1994). Synergistic interaction between cisplatin and paclitaxel in human ovarian carcinoma cells in vitro. Br. J. Cancer, 69, 299-306.
4. KRISHAN A. (1975). Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol., 66, 188-193.
5. MASUDA H, OZOLS RF, LAI GM, FOJO A, ROTHENBERG M AND HAMILTON TC. (1988). Increased DNA repair as a mechanism of acquired resistance to cisdiaminodichloroplatinum in human ovarian cancer cell lines. Cancer Res., 48, 5713-5716.
6. MCGUIRE WP, HOSKINS WJ, BRADY MF, KUGERA PR, PARTRIDGE EE, LOOKKY P, FARSON DLC AND DAVIDSON M. (1993). A phase III trial comparing cisplatin/cytoxan and cisplatin/taxol in advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol., 12, A808.
7. OZOLS RF. (1985). The case for combination chemotherapy in the treatment of advanced ovarian cancer. J. Clin. Oncol., 3, 1445-1447.
8. ROGAN AM, HAMILTON TC, YOUNG RC, KLECKER RW AND OZOLS RF. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science, 224, 994-999.
9. ROWINSKY EK, GILBERT MR, MCGUIRE WP, NOE DA, GROCHON LB, FORASTIERE AA, ETTINGER DS, LUBEJKO BG, CLARK B, SARTORIUS SE, CORNBLATH DR, HENDRICKS CB AND DONEHOWER RC. (1991) Sequences of paclitaxel and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol., 9, 1692-1703.
10. SKEHAN P, STORENG R, SCUDIERO D, MONKS A, MCMAHON J, VISTICA D, WARREN JT, BOKESCH H, KENNEY S AND BOYD MR. (1990). New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl Cancer Inst., 82, 1107-1112.
11. THIGPEN JT, BLESSING JA, BALL H, HUMMELS J AND BARRETT RJ. (1994). Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum based chemotherapy: A gynecologic oncology group study. J. Clin. Oncol., 12, 1748-1753.
12. VANHOEFER U, HARSTRICK A, WILKE H, SCHLEUCHER N, WALLES H, SCHRÖDER J AND SEEBER S. (1995). Schedule-dependent antagonism of paclitaxel in human gastric and ovarian carcinoma cell lines in vitro. Eur. J. Cancer, 31A(1), 92-97.